Our first quarter results reflect our continuing efforts on profitability focus and cost control. We dynamically adjusted our product mix to minimize the negative impact from the increased costs of certain raw materials and the government's price reduction on certain drugs. In addition, we believe our continued investments in CAPEX and R&D will give us a competitive advantage in for the long term, especially under the stricter regulatory environment.
Our growth in 2010 was consistent with our expectations and reflects our continued efforts on profitability focus and cost control. We dynamically adjust our product mix to minimize the negative impact from the increased cost of certain raw materials, as well as the government's price cut on certain drugs. In addition, our long-term investments in science and technology have achieved initial results, which were demonstrated by the strong sales from the new products supported by our R&D efforts. Overall, we remain enthusiastic about the tremendous opportunities in China's healthcare sector, and we are looking forward to more progress in the fiscal year ahead.
Going into 2010, we'll continue to strengthen our core competencies in production, sales and marketing and distribution reach, and we'll particularly focus on R&D efforts to ensure that we are well-prepared to capture the tremendous amount of opportunities in China's dynamic healthcare sector.